Neurocrine Biosciences saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 66 to 71.
Can You Really Time The Stock Market?
IBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the top-performing stocks tend to have an RS Rating of above 80 as they launch their largest runs. See if Neurocrine Biosciences can continue to show renewed price strength and clear that threshold.
Neurocrine Biosciences is now considered extended and out of buy range after clearing a 130.46 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 1%, compared to -42% in the prior report. Revenue increased from 11% to 16%. Keep an eye out for the company's next round of numbers on or around Oct. 28.
Neurocrine Biosciences holds the No. 43 rank among its peers in the Medical-Biomed/Biotech industry group. argenx ADR, Aurinia Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
